Diagnosis and Monitoring of Urological Tumors Using Positron Emission Tomography

Höfer, Christian; Kübler, Hubert; Härtung, R.; Breul, J.; Avril, Norbert

doi:10.1159/000049823

Cited by 54 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heicappell et al [11] reported a series of 8 TCC patients; 3 patients had nodal metastases, of whom 2 showed increased uptake by PET for a sensitivity of 66.7%. However, most investigators have felt the use of FDG PET has limited usefulness for metastatic urothelial tumors due to the erratic uptake of the isotope [5][6][7][8] . Our fi ndings support the opinion that FDG PET is unreliable for the detection of metastatic TCC fol- lowing chemotherapy but uptake is not as erratic in untreated metastatic TCC.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Fluorodeoxyglucose Positron Emission Tomography Imaging in Metastatic Transitional Cell Carcinoma with and without Prior Chemotherapy

Liu¹,

Lai²,

Espiritu

et al. 2006

Urol Int

View full text Add to dashboard Cite

Introduction: This study was designed to determine the value of fluorodeoxyglucose (FDG) positron emission tomography (PET) in the evaluation of metastatic transitional cell carcinoma (TCC). Methods: Fifty-eight FDG PET scans were performed on 46 consecutive patients with TCC. Results were correlated with radiologic, pathologic, and histologic findings in these patients and the sensitivity of PET for detecting malignancy in untreated TCC patients (n = 48) was compared to the sensitivity in patients who had undergone prior chemotherapy (n = 10). Results: Of 48 scans in patients who had no prior systemic chemotherapy, 10 had increased uptake in proven metastatic TCC lesions and 3 PET studies failed to reveal metastatic TCC (sensitivity 76.9%). In patients free of metastatic disease, 33 revealed no abnormal uptake and 1 study revealed a suspicious area in a patient free of metastases (specificity = 97.1%). However, in 10 patients imaged after receiving chemotherapy, the sensitivity fell to 50% for the detection of histologically confirmed residual/recurrent tumor by PET. Conclusions: FDG PET detects increased metabolic activity. After chemotherapy, viable cancer cells may still be present but with a diminished metabolic rate. As a result, PET imaging is often useful in the evaluation of untreated metastatic TCC metastasis but should be interpreted with caution in patients who have received prior chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Fluorodeoxyglucose Positron Emission Tomography Imaging in Metastatic Transitional Cell Carcinoma with and without Prior Chemotherapy

Liu¹,

Lai²,

Espiritu

et al. 2006

Urol Int

View full text Add to dashboard Cite

show abstract

“…False-negative and the unsatisfactory sensitivity may be given in following conditions. Micro-tumor and micrometastases have lower uptake values which might be masked by the higher uptake of the primary tumor, which can infect the false-negative results (Hoekstra et al, 1993;Cremerius et al, 1998;Hofer et al, 2001;Spermon et al, 2002;Antoch et al, 2004). In addition, timing of the PET scan is important, for patients examined within 10-14 days of chemotherapy may result in false-negative (Cremerius et al, 1998, Hain, 2005.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

Zhao

Ma²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…51 Thus, PET currently only has a role in evaluating aggressive advanced prostate cancer patients. However, recent efforts suggest a promising role for PET imaging in prostate cancer patients with recurrent disease at PSA relapse using 11-C-acetate, 52 and more recently, 11-C-choline.…”

Section: Discussion/future Directionsmentioning

confidence: 99%

The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients

Jani¹,

Liauw²,

Blend³

2007

Clinical Medicine & Research

View full text Add to dashboard Cite

Indium-111 radioimmunoscintigraphy (RIS) has an increasing role in the treatment of prostate cancer and is most commonly performed at this disease site using labeled monoclonal antibody against prostate-specific membrane antigen. There are many limitations of RIS, including low spatial resolution, low diagnostic yield and limited availability. Despite these limitations, the efficacy of RIS has been demonstrated in many clinical studies, including multi-institutional investigations. The highest sensitivity and specificity of RIS appears to be in the post-radical retropubic prostatectomy (post-RRP) setting. RIS has recently been explored for its role in clinical radiotherapy decision-making, and was found to have a significant impact in selecting patients for radiotherapy and for the general radiotherapy treatment volume definition. RIS has also recently been explored for its role in radiotherapy planning and was found to impact clinical target volume design. However, manual editing of the RIS volume is still necessary when projected into the radiotherapy-planning scan, as there is often overlap in the RIS-defined uptake regions with normal structures (rectum, bladder and symphysis bone marrow). The impact of RIS on biochemical control has been explored, with studies in this area yielding conflicting results. It appears that the maximum impact of RIS is possible when areas of labeled antibody uptake regions are co-registered with the radiotherapy-planning computed tomography scan.The larger RIS-guided target volumes do not appear to be prohibitive in increasing radiotherapy-related toxicity. Future directions of the use of RIS for post-RRP prostate cancer are discussed.

show abstract

Diagnosis and Monitoring of Urological Tumors Using Positron Emission Tomography

Cited by 54 publications

References 37 publications

Evaluation of Fluorodeoxyglucose Positron Emission Tomography Imaging in Metastatic Transitional Cell Carcinoma with and without Prior Chemotherapy

Evaluation of Fluorodeoxyglucose Positron Emission Tomography Imaging in Metastatic Transitional Cell Carcinoma with and without Prior Chemotherapy

Diagnostic Accuracy of 18F-FDG-PET in Patients with Testicular Cancer: a Meta-analysis

The Role of Indium-111 Radioimmunoscintigraphy in Post-Radical Retropubic Prostatectomy Management of Prostate Cancer Patients

Contact Info

Product

Resources

About